Rachel E J Besser1, Sarah E Flanagan2, Deborah G J Mackay3, I K Temple3, Maggie H Shepherd4, Beverley M Shields4, Sian Ellard2, Andrew T Hattersley5. 1. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom; Institute of Child Health, University College London, London, United Kingdom; 2. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom; 3. Faculty of Medicine, University of Southampton, Southampton, United Kingdom; University Hospital Southampton National Health Service Foundation Trust, Southampton, United Kingdom; and. 4. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom; National Institute for Health Research Exeter Clinical Research Facility, Royal Devon & Exeter National Health Service Foundation Trust, Exeter, United Kingdom. 5. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom; a.t.hattersley@exeter.ac.uk.
Abstract
BACKGROUND: Hyperglycemia in premature infants is usually thought to reflect inadequate pancreatic development rather than monogenic neonatal diabetes. No studies, to our knowledge, have investigated the prevalence of monogenic forms of diabetes in preterm infants. METHODS: We studied 750 patients with diabetes diagnosed before 6 months of age. We compared the genetic etiology and clinical characteristics of 146 preterm patients born <37 weeks and compared them with 604 born ≥37 weeks. RESULTS: A genetic etiology was found in 97/146 (66%) preterm infants compared with 501/604 (83%) born ≥37weeks, P < .0001. Chromosome 6q24 imprinting abnormalities (27% vs 12%, P = .0001) and GATA6 mutations (9% vs 2%, P = .003) occurred more commonly in preterm than term infants while mutations in KCNJ11 were less common (21 vs 34%, P = .008). Preterm patients with an identified mutation were diagnosed later than those without an identified mutation (median [interquartile range] 35 [34 to 36] weeks vs 31 [28 to 36] weeks, P < .0001). No difference was seen in other clinical characteristics of preterm patients with and without an identified mutation including age of presentation, birth weight, and time to referral. CONCLUSIONS: Patients with neonatal diabetes due to a monogenic etiology can be born preterm, especially those with 6q24 abnormalities or GATA6 mutations. A genetic etiology is more likely in patients with less severe prematurity (>32 weeks). Prematurity should not prevent referral for genetic testing as 37% have a potassium channel mutation and as a result can get improved control by replacing insulin with sulphonylurea therapy.
BACKGROUND:Hyperglycemia in premature infants is usually thought to reflect inadequate pancreatic development rather than monogenic neonatal diabetes. No studies, to our knowledge, have investigated the prevalence of monogenic forms of diabetes in preterminfants. METHODS: We studied 750 patients with diabetes diagnosed before 6 months of age. We compared the genetic etiology and clinical characteristics of 146 pretermpatients born <37 weeks and compared them with 604 born ≥37 weeks. RESULTS: A genetic etiology was found in 97/146 (66%) preterminfants compared with 501/604 (83%) born ≥37weeks, P < .0001. Chromosome 6q24 imprinting abnormalities (27% vs 12%, P = .0001) and GATA6 mutations (9% vs 2%, P = .003) occurred more commonly in preterm than term infants while mutations in KCNJ11 were less common (21 vs 34%, P = .008). Pretermpatients with an identified mutation were diagnosed later than those without an identified mutation (median [interquartile range] 35 [34 to 36] weeks vs 31 [28 to 36] weeks, P < .0001). No difference was seen in other clinical characteristics of pretermpatients with and without an identified mutation including age of presentation, birth weight, and time to referral. CONCLUSIONS:Patients with neonatal diabetes due to a monogenic etiology can be born preterm, especially those with 6q24 abnormalities or GATA6 mutations. A genetic etiology is more likely in patients with less severe prematurity (>32 weeks). Prematurity should not prevent referral for genetic testing as 37% have a potassium channel mutation and as a result can get improved control by replacing insulin with sulphonylurea therapy.
Authors: Joy E Lawn; Michael G Gravett; Toni M Nunes; Craig E Rubens; Cynthia Stanton Journal: BMC Pregnancy Childbirth Date: 2010-02-23 Impact factor: 3.007
Authors: Andrey P Babenko; Michel Polak; Hélène Cavé; Kanetee Busiah; Paul Czernichow; Raphael Scharfmann; Joseph Bryan; Lydia Aguilar-Bryan; Martine Vaxillaire; Philippe Froguel Journal: N Engl J Med Date: 2006-08-03 Impact factor: 91.245
Authors: Elisa De Franco; Sarah E Flanagan; Jayne A L Houghton; Hana Lango Allen; Deborah J G Mackay; I Karen Temple; Sian Ellard; Andrew T Hattersley Journal: Lancet Date: 2015-07-28 Impact factor: 79.321
Authors: Elisa De Franco; Charles Shaw-Smith; Sarah E Flanagan; Maggie H Shepherd; Andrew T Hattersley; Sian Ellard Journal: Diabetes Date: 2012-12-06 Impact factor: 9.461
Authors: Yasemin Denkboy Öngen; Erdal Eren; Özgecan Demirbaş; Elif Sobu; Sian Ellard; Elisa De Franco; Ömer Tarım Journal: J Clin Res Pediatr Endocrinol Date: 2020-08-21
Authors: Can Thi Bich Ngoc; Tran Minh Dien; Elisa De Franco; Sian Ellard; Jayne A L Houghton; Nguyen Ngoc Lan; Bui Phuong Thao; Nguyen Ngoc Khanh; Sarah E Flanagan; Maria E Craig; Vu Chi Dung Journal: Front Endocrinol (Lausanne) Date: 2021-09-09 Impact factor: 5.555